Aripiprazole

ARIPIPRAZOLE N-OXIDE ISOMER

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

Aripiprazole-d8 is a deuterated version of Aripiprazole, which is a selective D2DR (dopamine D2-receptor) antagonist with dopamine autoreceptor agonist activity. Users have reported separation of this compound and aripiprazole under reverse-phase H

Aripiprazole-d8 is a deuterated version of Aripiprazole, which is a selective D2DR (dopamine D2-receptor) antagonist with dopamine autoreceptor agonist activity. Users have reported separation of this compound and aripiprazole under reverse-phase H

N-ALKYL ARIPIPRAZOLE

Aripiprazole is a second generation atypical antipsychotic that also exhibits neuromodulatory, antidepressant, anxiolytic, antipsychotic, cognition enhancing, and antioxidative activities. Aripiprazole acts as a partial agonist at D2 receptors and

Aripiprazole is a second generation atypical antipsychotic that also exhibits neuromodulatory, antidepressant, anxiolytic, antipsychotic, cognition enhancing, and antioxidative activities. Aripiprazole acts as a partial agonist at D2 receptors and

Aripiprazole is a second generation atypical antipsychotic that also exhibits neuromodulatory, antidepressant, anxiolytic, antipsychotic, cognition enhancing, and antioxidative activities. Aripiprazole acts as a partial agonist at D2 receptors and